Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Dividends Paid?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Dividends Paid is 
0.0 (1Y - )

ALXN Stock Price & Dividends Paid

Dividends Paid for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Dividends Paid

chevron_right 2021 0.0 0
( 0 / year avg)
chevron_left 1995 0.0
vertical_align_top Peak 0.0 -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 0 0 of 27
years up.
arrow_drop_down # Down Years 0
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or 0% the rate relative to it's dividends paid over the same period.
  • If ALXN shrinks it's stock at the same rate as it's dividends paid (0/year) , it's stock price will shrink 0 and hit $0 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 0 years (0%) it's dividends paid were also up.
  • ALXN Historical Dividends Paid Table

    Year Dividends Paid YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.0 - - -
    4/1/2020 0.0 - - -
    4/1/2019 0.0 - - -
    4/1/2018 0.0 - - -
    4/1/2017 0.0 - - -
    4/1/2016 0.0 - - -
    4/1/2015 0.0 - - -
    4/1/2014 0.0 - - -
    4/1/2013 0.0 - - -
    4/1/2012 0.0 - - -
    4/1/2011 0.0 - - -
    4/1/2010 0.0 - - -
    4/1/2009 0.0 - - -
    4/1/2008 0.0 - - -
    4/1/2007 0.0 - - -
    4/1/2006 0.0 - - -
    4/1/2005 0.0 - - -
    4/1/2004 0.0 - - -
    4/1/2003 0.0 - - -
    4/1/2002 0.0 - - -
    4/1/2001 0.0 - - -
    4/1/2000 0.0 - - -
    4/1/1999 0.0 - - -
    4/1/1998 0.0 - - -
    4/1/1997 0.0 - - -
    4/1/1996 0.0 - - -
    4/1/1995 0.0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The total dividends paid to shareholders.

    For more detailed definitions, please see Investopedia.